Free tool
FAERS Monitor: Fulphila
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761075 or its brand name (Fulphila, Pegfilgrastim-Jmdb). Reports on generic versions are filed under their own applications.
Reports
452
Serious
294
65% of reports
Hospitalization
146
Death reported
86
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- death70
- off label use29
- drug ineffective25
- nausea25
- febrile neutropenia22
- neutropenia22
- product quality issue21
- diarrhoea18
- hospitalisation18
- vomiting18
- device leakage17
- pyrexia17
- needle issue15
- fatigue13
- product dose omission issue13
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2018 | 10 |
| 2019 | 29 |
| 2020 | 40 |
| 2021 | 52 |
| 2022 | 37 |
| 2023 | 53 |
| 2024 | 108 |
| 2025 | 95 |
| 2026 | 28 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,707 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| needle issueSignal | 15 | 24.0 | 14.6 | 308 |
| device leakageSignal | 17 | 18.3 | 11.4 | 261 |
| febrile neutropeniaSignal | 22 | 15.4 | 10.3 | 284 |
| neutropeniaSignal | 22 | 7.5 | 5.0 | 119 |
| product quality issueSignal | 21 | 7.2 | 4.7 | 107 |
| hospitalisationSignal | 18 | 5.5 | 3.5 | 62 |
| deathSignal | 70 | 3.8 | 3.0 | 146 |
| pyrexiaSignal | 17 | 2.3 | 1.4 | 11 |
| product dose omission issueSignal | 13 | 2.1 | 1.2 | 6 |
| vomiting | 18 | 1.8 | 1.1 | 6 |
| off label use | 29 | 1.5 | 1.1 | 5 |
| nausea | 25 | 1.5 | 1.0 | 3 |
| diarrhoea | 18 | 1.3 | 0.8 | 1 |
| drug ineffective | 25 | 0.9 | 0.6 | 0 |
| fatigue | 13 | 0.8 | 0.5 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.